Crept accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes

Cancer Cell

Volumn 21, Issue 1, 2012, Pages 92-104

  Lu, Dongdong ^a,b   Wu, Yinyuan ^a   Wang, Yinyin ^a   Ren, Fangli ^a   Wang, Dianjun ^c   Su, Fuqin ^a   Zhang, Yanquan ^a   Yang, Xi ^a   Jin, Guihua ^a   Hao, Xinbao ^a   He, Dacheng ^d   Zhai, Yonggong ^d   Irwin, David M ^e   Hu, Jim ^f   Sung, JosephJ Y ^g   Yu, Jun ^g   Jia, Baoqing ^c   Chang, Zhijie ^a  

^a Tsinghua University   (China)

^b TONGJI UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING NORMAL UNIVERSITY   (China)

^e UNIVERSITY OF TORONTO   (Canada)

^f HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE RELATED AND EXPRESSION ELEVATED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 84862948460     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.12.016     Document Type: Article

References (42)

1. Bonetta L. Going on a cancer gene hunt. Cell 2005, 123:735-737.
2. Buratowski S. Progression through the RNA polymerase II CTD cycle. Mol. Cell 2009, 36:541-546.
3. Connelly S., Manley J.L. A CCAAT box sequence in the adenovirus major late promoter functions as part of an RNA polymerase II termination signal. Cell 1989, 57:561-571.
4. Dekker J., Rippe K., Dekker M., Kleckner N. Capturing chromosome conformation. Science 2002, 295:1306-1311.
5. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., Lowe S.W. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 2005, 37:1289-1295.
6. Doerks T., Copley R.R., Schultz J., Ponting C.P., Bork P. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res. 2002, 12:47-56.
7. Eeckhoute J., Carroll J.S., Geistlinger T.R., Torres-Arzayus M.I., Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006, 20:2513-2526.
8. Felsher D.W. Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Cancer 2003, 3:375-380.
9. Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G., Sugarbaker D.J., Bueno R. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. 2005, 166:1827-1840.
10. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68:67-108.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Herber B., Truss M., Beato M., Müller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 1994, 9:1295-1304.
13. Hunter T., Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582.
14. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999, 39:295-312.
15. Kim M., Krogan N.J., Vasiljeva L., Rando O.J., Nedea E., Greenblatt J.F., Buratowski S. The yeast Rat1 exonuclease promotes transcription termination by RNA polymerase II. Nature 2004, 432:517-522.
16. Lee M.H., Yang H.Y. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 2003, 22:435-449.
17. Lian Z., Karpikov A., Lian J., Mahajan M.C., Hartman S., Gerstein M., Snyder M., Weissman S.M. A genomic analysis of RNA polymerase II modification and chromatin architecture related to 3' end RNA polyadenylation. Genome Res. 2008, 18:1224-1237.
18. Liu J., Liu H., Zhang X., Gao P., Wang J., Hu Z. Identification and characterization of P15RS, a novel P15(INK4b) related gene on G1/S progression. Biochem. Biophys. Res. Commun. 2002, 299:880-885.
19. Lunde B.M., Reichow S.L., Kim M., Suh H., Leeper T.C., Yang F., Mutschler H., Buratowski S., Meinhart A., Varani G. Cooperative interaction of transcription termination factors with the RNA polymerase II C-terminal domain. Nat. Struct. Mol. Biol. 2010, 17:1195-1201.
20. Luo W., Bentley D. A ribonucleolytic rat torpedoes RNA polymerase II. Cell 2004, 119:911-914.
21. Mapendano C.K., Lykke-Andersen S., Kjems J., Bertrand E., Jensen T.H. Crosstalk between mRNA 3' end processing and transcription initiation. Mol. Cell 2010, 40:410-422.
22. Massagué J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306.
23. Moore M.J., Proudfoot N.J. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 2009, 136:688-700.
24. O'Sullivan J.M., Tan-Wong S.M., Morillon A., Lee B., Coles J., Mellor J., Proudfoot N.J. Gene loops juxtapose promoters and terminators in yeast. Nat. Genet. 2004, 36:1014-1018.
25. Obaya A.J., Sedivy J.M. Regulation of cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 2002, 59:126-142.
26. Osborne C., Wilson P., Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004, 9:361-377.
27. Perkins K.J., Lusic M., Mitar I., Giacca M., Proudfoot N.J. Transcription-dependent gene looping of the HIV-1 provirus is dictated by recognition of pre-mRNA processing signals. Mol. Cell 2008, 29:56-68.
28. Polsky D., Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003, 22:3087-3091.
29. Proudfoot N.J. How RNA polymerase II terminates transcription in higher eukaryotes. Trends Biochem. Sci. 1989, 14:105-110.
30. Rong Y., Cheng L., Ning H., Zou J., Zhang Y., Xu F., Liu L., Chang Z., Fu X.Y. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res. 2006, 66:8049-8057.
31. Scholes D.T., Banerjee M., Bowen B., Curcio M.J. Multiple regulators of Ty1 transposition in Saccharomyces cerevisiae have conserved roles in genome maintenance. Genetics 2001, 159:1449-1465.
32. Semczuk A., Jakowicki J.A. Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett. 2004, 203:1-12.
33. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
34. Sui G., Soohoo C., Affar B., Gay F., Shi Y., Forrester W.C., Shi Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 2002, 99:5515-5520.
35. Tan-Wong S.M., French J.D., Proudfoot N.J., Brown M.A. Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene. Proc. Natl. Acad. Sci. USA 2008, 105:5160-5165.
36. Tong A.H., Evangelista M., Parsons A.B., Xu H., Bader G.D., Pagé N., Robinson M., Raghibizadeh S., Hogue C.W., Bussey H., et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294:2364-2368.
37. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
38. Wu Y., Zhang Y., Zhang H., Yang X., Wang Y., Ren F., Liu H., Zhai Y., Jia B., Yu J., Chang Z. p15RS attenuates Wnt/beta-catenin signaling by disrupting beta-catenin·TCF4 Interaction. J.Biol. Chem. 2010, 285:34621-34631.
39. Yamasaki L., Pagano M. Cell cycle, proteolysis and cancer. Curr. Opin. Cell Biol. 2004, 16:623-628.
40. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am. J. Pharmacogenomics 2005, 5:173-190.
41. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., Wang H. Oncogenes as novel targets for cancer therapy (part II): intermediate signaling molecules. Am. J. Pharmacogenomics 2005, 5:247-257.
42. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., Wang H. Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am. J. Pharmacogenomics 2005, 5:327-338.